IRIXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends January 3
IRIDEX CORP
Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 18, 2026
$0.77−0.04 (-5.48%)
Close on Oct 19, 2026
- Market cap
- $13.41M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.2700 (−25.96%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
IRIDEX CORP grew revenue 3.7% to $51.57M over the twelve months to Jul 4, 2026. Free cash flow was -$2.00M.
Revenue
$51.57M
+3.7% vs. a year earlier
Operating income
-$2.78M
TTM Q2 2026
Free cash flow
-$2.00M
TTM Q2 2026
EPS, diluted
-$0.20
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 4, 2026
Valuation
- Market cap
- $13.41M
- P/E ratio
- –
- Price to sales
- 0.26
- Price to book
- 3.69
- Dividend yield
- –
- Free cash flow yield
- -14.91%
Fundamentals
- Revenue
- $51.57M
- Net income
- -$3.55M
- EPS, diluted
- -$0.20
- Free cash flow
- -$2.00M
- Book value per share
- $0.21
- Diluted shares
- 17M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$51.57M+3.7% YoY
Gross profit
$18.53M-5.7% YoY
Operating income
-$2.78M
Net income
-$3.55M
EPS, diluted
-$0.20
Free cash flow
-$2.00M
Reported periodTrailing twelve months